Aptevo/Alligator Phase 1 ALG.APV-527 trial: 60% stable disease, 11+ month duration in breast cancer

Aptevo Therapeutics Inc.

Phase 1 data presented at ESMO: 9 of 15 evaluable patients (60%) achieved stable disease across solid tumors.
Breast cancer patient with progressive disease at entry achieved SD for >11 months and dose-escalated twice.
Colon cancer patient with sustained SD remains on study for over 4 months.
No maximum tolerated dose identified; safety profile positive across all cohorts.
Serum concentrations consistent with dose and preclinical predictions; biomarker analyses confirm biological activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.